ECSP099373A - Inhibidores de transcriptasa inversa no nucleosídicos - Google Patents

Inhibidores de transcriptasa inversa no nucleosídicos

Info

Publication number
ECSP099373A
ECSP099373A EC2009009373A ECSP099373A ECSP099373A EC SP099373 A ECSP099373 A EC SP099373A EC 2009009373 A EC2009009373 A EC 2009009373A EC SP099373 A ECSP099373 A EC SP099373A EC SP099373 A ECSP099373 A EC SP099373A
Authority
EC
Ecuador
Prior art keywords
nucleosidal
compounds
prophylaxis
formula
reverse transcriptase
Prior art date
Application number
EC2009009373A
Other languages
English (en)
Inventor
Neville J Anthony
Robert P Gomez
Samson M Jolly
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP099373A publication Critical patent/ECSP099373A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

RESUMEN DE LA INVENCIÓNLos compuestos de la Fórmula I: (I),son inhibidores de transcriptasa inversa de VIH, en la que Q, R2, R3, R6, T1, T2, y T3 se definene en el presente documento. Los compuestos de la Fórmula I, y sus sales y profármacos farmacéuticamente aceptables, son de utilidad en la inhibición de transcriptasa inversa de VIH, en la profilaxis y tratamiento de infección por VIH y en la profilaxis, retraso del inicio o de la progresión, y tratamiento del SIDA. Los compuestos y sus sales pueden emplearse como ingredientes en composiciones farmacéuticas, opcionalmente combinados con otros antivirales, inmunomoduladores, antibióticos o vacunas.
EC2009009373A 2006-12-13 2009-06-01 Inhibidores de transcriptasa inversa no nucleosídicos ECSP099373A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87462906P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
ECSP099373A true ECSP099373A (es) 2009-07-31

Family

ID=39277099

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009373A ECSP099373A (es) 2006-12-13 2009-06-01 Inhibidores de transcriptasa inversa no nucleosídicos

Country Status (29)

Country Link
US (2) US7781454B2 (es)
EP (1) EP2121638B1 (es)
JP (1) JP5123949B2 (es)
KR (1) KR20090087481A (es)
CN (1) CN101558050A (es)
AR (1) AR064199A1 (es)
AU (1) AU2007334598B2 (es)
BR (1) BRPI0720196A2 (es)
CA (1) CA2673093A1 (es)
CL (1) CL2007003594A1 (es)
CR (1) CR10843A (es)
DO (1) DOP2009000138A (es)
EA (1) EA200970572A1 (es)
EC (1) ECSP099373A (es)
GE (1) GEP20115320B (es)
GT (1) GT200900158A (es)
HN (1) HN2009001160A (es)
IL (1) IL199103A0 (es)
MA (1) MA31036B1 (es)
MX (1) MX2009006285A (es)
NI (1) NI200900103A (es)
NO (1) NO20092636L (es)
NZ (1) NZ577637A (es)
PE (1) PE20081448A1 (es)
SV (1) SV2009003294A (es)
TN (1) TN2009000243A1 (es)
TW (1) TW200831085A (es)
WO (2) WO2008076225A2 (es)
ZA (1) ZA200903395B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5269087B2 (ja) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
CN101952274A (zh) * 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
WO2009117278A2 (en) * 2008-03-20 2009-09-24 Merck & Co., Inc. Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
CN102666537A (zh) * 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
MX2012011379A (es) 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US20120142627A1 (en) * 2010-12-06 2012-06-07 Emory University Monophosphate prodrugs of dapd and analogs thereof
CN103732216A (zh) * 2011-08-16 2014-04-16 默沙东公司 无机基质和有机聚合物组合用于制备稳定的无定形分散体的用途
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN103848827A (zh) * 2012-11-30 2014-06-11 南京大学 一种含苯并三氮唑类衍生物在抗癌药物中的应用
CN103848826A (zh) * 2012-11-30 2014-06-11 南京大学 一类含苯并三氮唑结构的1,3,4-恶二唑类衍生物的制法与用途
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
CN105906482B (zh) * 2016-05-19 2019-02-12 江苏优嘉植物保护有限公司 一种利用2,5-二氯酚醚制备2,5-二氯苯酚的方法
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
EP3986477A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma A/S CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
EP4069212A4 (en) * 2019-12-04 2024-03-06 Arcus Biosciences, Inc. INHIBITORS OF HIF-2ALPHA
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
WO2026042788A1 (ja) * 2024-08-20 2026-02-26 塩野義製薬株式会社 複素環誘導体
WO2026120176A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Conjugates comprising an aromatic carbamate-derived reversible linker

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
SU1049487A1 (ru) * 1982-06-24 1983-10-23 Новокузнецкий научно-исследовательский химико-фармацевтический институт Способ получени @ -аминокетонов бензимидазольного р да
US5358950A (en) * 1991-07-05 1994-10-25 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists
US5527819A (en) * 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0963371B1 (en) * 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
US6977262B2 (en) * 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
EP1545510A4 (en) * 2002-08-07 2006-11-15 Idenix Cayman Ltd SUBSTITUTED PHENYLINDOLE FOR THE TREATMENT OF HIV
AU2003269327A1 (en) * 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR101099281B1 (ko) * 2003-03-03 2011-12-26 어레이 바이오파마 인크. ｐ38 억제제 및 그의 사용 방법
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
KR100844864B1 (ko) * 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
CN1926139A (zh) * 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7625949B2 (en) * 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
WO2005115147A2 (en) 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
ES2391461T3 (es) * 2004-07-27 2012-11-27 F. Hoffmann-La Roche Ag Compuestos de benciltriazolona utilizados como inhibidores no nucleósidos de transcriptasa inversa
AU2006227394A1 (en) * 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
JP2008546839A (ja) 2005-06-28 2008-12-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド逆転写酵素阻害剤
JP2008546837A (ja) 2005-06-28 2008-12-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド逆転写酵素阻害剤
AU2006261954A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
DE602007013573D1 (de) * 2006-08-16 2011-05-12 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
AU2007321376A1 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
WO2008076223A1 (en) 2008-06-26
TN2009000243A1 (en) 2010-10-18
NZ577637A (en) 2011-05-27
WO2008076225A2 (en) 2008-06-26
CR10843A (es) 2009-08-12
TW200831085A (en) 2008-08-01
CL2007003594A1 (es) 2008-05-30
GT200900158A (es) 2009-10-14
NI200900103A (es) 2010-01-26
HN2009001160A (es) 2011-10-11
US20100286192A1 (en) 2010-11-11
US7781454B2 (en) 2010-08-24
EP2121638B1 (en) 2016-05-25
CA2673093A1 (en) 2008-06-26
MA31036B1 (fr) 2009-12-01
KR20090087481A (ko) 2009-08-17
BRPI0720196A2 (pt) 2013-12-31
AU2007334598A1 (en) 2008-06-26
EA200970572A1 (ru) 2009-12-30
CN101558050A (zh) 2009-10-14
PE20081448A1 (es) 2008-10-19
IL199103A0 (en) 2010-03-28
JP5123949B2 (ja) 2013-01-23
ZA200903395B (en) 2010-05-26
US20080275097A1 (en) 2008-11-06
GEP20115320B (en) 2011-10-25
JP2010510989A (ja) 2010-04-08
AU2007334598B2 (en) 2013-01-17
MX2009006285A (es) 2009-06-23
EP2121638A2 (en) 2009-11-25
SV2009003294A (es) 2009-11-09
NO20092636L (no) 2009-09-08
WO2008076225A3 (en) 2008-08-07
DOP2009000138A (es) 2009-11-15
AR064199A1 (es) 2009-03-18

Similar Documents

Publication Publication Date Title
DOP2009000138A (es) Inhibidores de transcriptasa inversa no nucleósidicos
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
ECSP12012201A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
DOP2015000082A (es) Inhibidores no nucleósidos de la transcriptasa inversa
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
CR8569A (es) Inhibidores de integrasa de vih
DOP2016000265A (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
CO6382127A2 (es) Inhibidores de la integrasa del vih
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
DOP2006000176A (es) Inhibidores de la transcriptasa reversa de vih
MX2023009041A (es) Uso de inhibidores del proteasoma en el tratamiento de infecciones por coronavirus.
ECSP088126A (es) Inhibidores de la transcriptasa reversa de vih
DOP2005000105A (es) Inhibidores de la integrasa del vih